Disc Medicine (IRON) Accumulated Depreciation & Amortization (2020 - 2024)
Disc Medicine (IRON) reported Accumulated Depreciation & Amortization of -$185000.0 for Q4 2024, down 403.28% year-over-year from $61000.0 in Q1 2024, and down 214.91% on a QoQ basis from $161000.0 in Q3 2024.
Disc Medicine (IRON) has 5 years of Accumulated Depreciation & Amortization data on file, last reported at -$185000.0 in Q4 2024.
- Quarterly Accumulated Depreciation & Amortization fell 403.28% year-over-year to -$185000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$185000.0 (down 403.28% YoY) and the FY2024 annual result came in at -$185000.0, down 403.28% from the prior year.
- Accumulated Depreciation & Amortization retreated to -$185000.0 in Q4 2024 per IRON's latest filing, from $161000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $661000.0 in Q4 2020 and bottomed at -$185000.0 in Q4 2024.
- The 5-year median for Accumulated Depreciation & Amortization is $49000.0 (2023), against an average of $82454.5.
- The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization surged 354.17%; it then tumbled 403.28% in 2024.
- Tracing IRON's Accumulated Depreciation & Amortization over 5 years: stood at $661000.0 in 2020, then tumbled by 101.97% to -$13000.0 in 2021, then tumbled by 84.62% to -$24000.0 in 2022, then surged by 354.17% to $61000.0 in 2023, then plunged by 403.28% to -$185000.0 in 2024.
- Per Business Quant, the three latest IRON Accumulated Depreciation & Amortization figures stand at -$185000.0 (Q4 2024), $161000.0 (Q3 2024), and $142000.0 (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -185,000.00 |
| Dec 31, 2024 | -185,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | -36,000.00 |
| Mar 31, 2023 | -36,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Dec 31, 2021 | -13,000.00 |
| Dec 31, 2021 | -13,000.00 |
| Dec 31, 2020 | 661,000.00 |
| Dec 31, 2020 | 661,000.00 |